

Table 4.26

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	245,053	99.4%	202,614	99.4%	22,502	99.3%	16,944	99.3%	904	99.2%	22,162	99.1%
Epidermoid carcinoma ^d (8051-8131)	166	0.1%	127	0.1%	28	0.1%	-	-	-	-	-	-
Adenocarcinoma ^e	239,474	97.1%	198,334	97.3%	21,632	95.5%	16,610	97.4%	881	96.7%	21,506	96.1%
Adenocarcinoma, NOS (8140)	2,349	1.0%	1,893	0.9%	285	1.3%	133	0.8%	-	-	240	1.1%
Infiltrating duct carcinoma (8500)	171,398	69.5%	140,045	68.7%	16,465	72.7%	12,767	74.8%	673	73.9%	15,788	70.6%
Lobular carcinoma, NOS (8520)	19,969	8.1%	17,684	8.7%	1,307	5.8%	765	4.5%	59	6.5%	1,470	6.6%
Inflammatory adenocarcinoma (8530)	1,734	0.7%	1,401	0.7%	249	1.1%	70	0.4%	-	-	232	1.0%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	28,381	11.5%	24,503	12.0%	1,953	8.6%	1,613	9.5%	90	9.9%	2,429	10.9%
Mucinous adenocarcinoma (8480,8482)	5,979	2.4%	4,824	2.4%	498	2.2%	572	3.4%	22	2.4%	463	2.1%
Mucin-producing adenocarcinoma (8481)	119	0.0%	99	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	3,180	1.3%	2,896	1.4%	135	0.6%	110	0.6%	-	-	185	0.8%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,427	0.6%	1,031	0.5%	218	1.0%	152	0.9%	-	-	164	0.7%
Paget disease (8540-8543)	1,430	0.6%	1,166	0.6%	138	0.6%	116	0.7%	-	-	170	0.8%
Other adenocarcinomas ^f	3,508	1.4%	2,792	1.4%	369	1.6%	308	1.8%	-	-	358	1.6%
Other specific carcinomas ^g	2,621	1.1%	1,943	1.0%	492	2.2%	159	0.9%	-	-	339	1.5%
Medullary adenocarcinoma (8510-8513)	1,341	0.5%	944	0.5%	295	1.3%	87	0.5%	-	-	217	1.0%
Other ^h	1,280	0.5%	999	0.5%	197	0.9%	72	0.4%	-	-	122	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	2,792	1.1%	2,210	1.1%	350	1.5%	167	1.0%	-	-	302	1.4%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

ⁱ Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	309	0.1%	256	0.1%	31	0.1%	16	0.1%	-	-	22	0.1%
Hemangiosarcomas (9120-9126,9170)	151	0.1%	135	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^d	158	0.1%	121	0.1%	23	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	688	0.3%	519	0.3%	74	0.3%	77	0.5%	-	-	126	0.6%
Phyllodes tumor, malignant (9020)	564	0.2%	426	0.2%	54	0.2%	68	0.4%	-	-	107	0.5%
Other ^e	124	0.1%	93	0.0%	20	0.1%	-	-	-	-	19	0.1%
Unspecified (8000-8005)	450	0.2%	353	0.2%	52	0.2%	20	0.1%	-	-	59	0.3%
Total ^f	246,500	100.0%	203,742	100.0%	22,659	100.0%	17,057	100.0%	911	100.0%	22,369	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	60,394	99.7%	49,063	99.7%	5,355	99.4%	5,028	99.8%	164	100.0%	4,920	99.7%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	18	0.0%	17	0.0%	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^f	50,554	83.4%	40,642	82.6%	4,644	86.2%	4,574	90.8%	127	77.4%	4,198	85.0%
Cribriform carcinoma <i>in situ</i> (8201/2)	4,844	8.0%	3,863	7.8%	403	7.5%	484	9.6%	17	10.4%	413	8.4%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	3,092	5.1%	2,584	5.3%	211	3.9%	269	5.3%	-	-	224	4.5%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	20,986	34.6%	17,054	34.7%	1,942	36.1%	1,687	33.5%	63	38.4%	1,675	33.9%
Comedocarcinoma <i>in situ</i> (8501/2)	4,568	7.5%	3,762	7.6%	396	7.4%	364	7.2%	-	-	386	7.8%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,144	1.9%	841	1.7%	156	2.9%	113	2.2%	-	-	97	2.0%
Noninfiltrating intracystic carcinoma(8504/2)	300	0.5%	211	0.4%	38	0.7%	47	0.9%	-	-	28	0.6%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,656	2.7%	1,335	2.7%	182	3.4%	113	2.2%	-	-	150	3.0%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	13,758	22.7%	10,820	22.0%	1,308	24.3%	1,473	29.2%	19	11.6%	1,205	24.4%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	6,974	11.5%	6,031	12.3%	466	8.7%	264	5.2%	21	12.8%	506	10.3%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	6,948	11.5%	6,009	12.2%	463	8.6%	263	5.2%	21	12.8%	506	10.3%
Lobular CIS ^f with other CIS ^f (8524/2)	24	0.0%	20	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,405	4.0%	2,025	4.1%	196	3.6%	152	3.0%	-	-	188	3.8%
Other adenocarcinomas ^g	443	0.7%	348	0.7%	49	0.9%	37	0.7%	-	-	28	0.6%
Other <i>in situ</i> histologies ^h	192	0.3%	148	0.3%	31	0.6%	-	-	-	-	16	0.3%
Total	60,586	100.0%	49,211	100.0%	5,386	100.0%	5,037	100.0%	164	100.0%	4,936	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,339	98.3%	11,644	98.2%	1,971	98.0%	1,408	98.7%	98	100.0%	3,610	98.8%
Epidermoid carcinoma ^d (8050-8131)	10,601	67.9%	7,903	66.7%	1,562	77.7%	920	64.5%	76	77.6%	2,628	71.9%
Squamous cell carcinoma (8070)	6,915	44.3%	5,082	42.9%	1,130	56.2%	570	40.0%	48	49.0%	1,542	42.2%
Squamous cell, keratinizing (8071)	1,175	7.5%	888	7.5%	167	8.3%	100	7.0%	-	-	361	9.9%
Squamous cell, non-keratinizing (8072)	1,479	9.5%	1,143	9.6%	162	8.1%	145	10.2%	-	-	428	11.7%
Squamous cell, Microinvasive (8076)	782	5.0%	610	5.1%	67	3.3%	75	5.3%	-	-	230	6.3%
Other (8050-8069, 8073-8075,8077-8131)	250	1.6%	180	1.5%	36	1.8%	30	2.1%	-	-	67	1.8%
Adenocarcinoma ^e	4,044	25.9%	3,239	27.3%	298	14.8%	423	29.7%	16	16.3%	837	22.9%
Adenocarcinoma, NOS (8140)	2,079	13.3%	1,673	14.1%	139	6.9%	218	15.3%	-	-	428	11.7%
Adenosquamous (8560,8570)	679	4.3%	524	4.4%	69	3.4%	76	5.3%	-	-	170	4.7%
Other adenocarcinomas ^f	1,286	8.2%	1,042	8.8%	90	4.5%	129	9.0%	-	-	239	6.5%
Other specific carcinomas ^g	236	1.5%	175	1.5%	28	1.4%	29	2.0%	-	-	46	1.3%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	458	2.9%	327	2.8%	83	4.1%	36	2.5%	-	-	99	2.7%
Sarcoma ^h	75	0.5%	61	0.5%	-	-	-	-	-	-	18	0.5%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	128	0.8%	95	0.8%	20	1.0%	-	-	-	-	17	0.5%
Unspecified (8000-8005)	69	0.4%	53	0.4%	-	-	-	-	-	-	-	-
Total	15,611	100.0%	11,853	100.0%	2,011	100.0%	1,426	100.0%	98	100.0%	3,655	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^h Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	171,276	99.5%	139,225	99.5%	17,491	99.5%	12,245	99.6%	787	98.9%	14,921	99.5%
Epidermoid carcinoma ^d (8051-8131)	739	0.4%	621	0.4%	91	0.5%	-	-	-	-	62	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	677	0.4%	566	0.4%	87	0.5%	-	-	-	-	53	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	162,777	94.6%	133,076	95.1%	16,236	92.3%	11,536	93.8%	732	92.0%	13,990	93.3%
Adenocarcinoma, NOS (8140)	112,318	65.3%	91,462	65.4%	11,299	64.3%	8,382	68.1%	547	68.7%	9,608	64.0%
Adenocarcinoma in adenomatous polyp (8210)	11,748	6.8%	9,505	6.8%	1,035	5.9%	964	7.8%	51	6.4%	926	6.2%
Adenocarcinoma in villous adenoma (8261)	5,354	3.1%	4,436	3.2%	534	3.0%	318	2.6%	16	2.0%	542	3.6%
Mucinous adenocarcinoma (8470-8473,8480,8482)	12,673	7.4%	10,749	7.7%	1,125	6.4%	682	5.5%	50	6.3%	1,185	7.9%
Mucin-producing adenocarcinoma (8481)	3,707	2.2%	2,999	2.1%	493	2.8%	187	1.5%	-	-	313	2.1%
Signet ring adenocarcinoma (8490)	1,964	1.1%	1,665	1.2%	156	0.9%	127	1.0%	-	-	170	1.1%
Other adenocarcinomas ^e	15,013	8.7%	12,260	8.8%	1,594	9.1%	876	7.1%	51	6.4%	1,246	8.3%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	6,182	3.6%	4,252	3.0%	988	5.6%	602	4.9%	43	5.4%	720	4.8%
Neuroendocrine carcinoid (8240-8245)	5,190	3.0%	3,420	2.4%	901	5.1%	547	4.4%	36	4.5%	636	4.2%
Other ^f	992	0.6%	832	0.6%	87	0.5%	55	0.4%	-	-	84	0.6%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,578	0.9%	1,276	0.9%	176	1.0%	97	0.8%	-	-	149	1.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	97	0.1%	74	0.1%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	211	0.1%	155	0.1%	28	0.2%	27	0.2%	-	-	20	0.1%
Unspecified (8000-8005)	514	0.3%	428	0.3%	50	0.3%	21	0.2%	-	-	50	0.3%
Total ^d	172,098	100.0%	139,882	100.0%	17,582	100.0%	12,300	100.0%	796	100.0%	15,001	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,853	99.1%	13,371	99.1%	1,628	99.3%	701	98.9%	68	100.0%	1,064	98.8%
Epidermoid carcinoma ^d (8051-8131)	5,722	35.8%	3,824	28.3%	1,341	81.8%	499	70.4%	34	50.0%	463	43.0%
Squamous cell carcinoma (8070-8078, 8083-8084)	5,706	35.7%	3,810	28.2%	1,340	81.8%	498	70.2%	34	50.0%	463	43.0%
Adenocarcinoma (8050,8140-8147,8160-8162, 8180-8221,8250-8507,8514, 8520-8551,8560,8570-8574, 8576,8940-8941)	9,236	57.8%	8,779	65.1%	215	13.1%	165	23.3%	29	42.6%	548	50.9%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	264	1.7%	227	1.7%	17	1.0%	-	-	-	-	17	1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	631	3.9%	541	4.0%	55	3.4%	23	3.2%	-	-	36	3.3%
Other specific types ^e (8680-8713,8720-8790, 8800-8921,8930-8936, 8950-9030,9040-9044, 9060-9110,9120-9136, 9150-9252,9260-9365, 9370-9373,9380-9539, 9540-9582)	42	0.3%	29	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	95	0.6%	89	0.7%	-	-	-	-	-	-	-	-
Total	15,990	100.0%	13,489	100.0%	1,639	100.0%	709	100.0%	68	100.0%	1,077	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Other specific types includes sarcomas and other soft tissue tumors.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	17,273	97.2%	11,962	97.0%	2,043	98.1%	3,048	97.8%	121	91.7%	2,789	96.3%
Epidermoid carcinoma ^d (8170-8175)	13,613	76.6%	9,139	74.1%	1,727	82.9%	2,568	82.4%	100	75.8%	2,290	79.1%
Cholangiocarcinoma (8050,8140-8141, 8160-8161,8260,8440, 8480-8500,8570-8572)	2,641	14.9%	2,089	16.9%	210	10.1%	313	10.0%	16	12.1%	354	12.2%
Intrahepatic cholangio- carcinoma (8160)	1,808	10.2%	1,421	11.5%	126	6.0%	236	7.6%	-	-	248	8.6%
Other cholangiocarcinoma (8050,8140-8141,8161, 8260,8440,8480-8500, 8570-8572)	833	4.7%	668	5.4%	84	4.0%	77	2.5%	-	-	106	3.7%
Other specific carcinomas ^e	394	2.2%	307	2.5%	36	1.7%	45	1.4%	-	-	46	1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	337	1.9%	236	1.9%	41	2.0%	56	1.8%	-	-	47	1.6%
Hepatoblastoma (8970)	179	1.0%	147	1.2%	-	-	16	0.5%	-	-	65	2.2%
Sarcoma ^f	152	0.9%	117	0.9%	-	-	20	0.6%	-	-	-	-
Hemangiosarcoma (9120-9133,9161)	90	0.5%	72	0.6%	-	-	-	-	-	-	-	-
Other sarcomas ^g	62	0.3%	45	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8969,8971-9030, 9060-9110,9260-9365,9380-9539)	46	0.3%	28	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	123	0.7%	84	0.7%	-	-	22	0.7%	-	-	16	0.6%
Total ^d	17,773	100.0%	12,338	100.0%	2,083	100.0%	3,117	100.0%	132	100.0%	2,896	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8177-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^g Sarcoma includes histologies 8680-8713, 8800-8921, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^h Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9135-9136, 9150-9160, 9170-9252, 9370-9373, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	198,736	98.9%	166,400	98.9%	20,038	99.0%	10,881	99.1%	690	98.0%	10,526	98.7%
Small cell (8041-8045)	27,826	13.9%	24,554	14.6%	2,167	10.7%	889	8.1%	135	19.2%	1,275	12.0%
Non-small cell ^d	170,910	85.1%	141,846	84.3%	17,871	88.3%	9,992	91.0%	555	78.8%	9,251	86.7%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	39,682	19.8%	33,213	19.7%	4,485	22.2%	1,668	15.2%	180	25.6%	1,837	17.2%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	75,367	37.5%	62,305	37.0%	7,249	35.8%	5,374	48.9%	161	22.9%	4,276	40.1%
Large cell (8011-8015)	6,544	3.3%	5,356	3.2%	807	4.0%	335	3.0%	22	3.1%	363	3.4%
Other non-small cell ^e	49,317	24.5%	40,972	24.4%	5,330	26.3%	2,615	23.8%	192	27.3%	2,775	26.0%
Sarcoma (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	355	0.2%	302	0.2%	27	0.1%	17	0.2%	-	-	29	0.3%
Other specified types ^f (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	144	0.1%	129	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	1,674	0.8%	1,414	0.8%	163	0.8%	83	0.8%	-	-	101	0.9%
Total	200,909	100.0%	168,245	100.0%	20,239	100.0%	10,985	100.0%	704	100.0%	10,666	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^g Other specific types includes melanomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Males by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	106,152	98.9%	87,652	98.9%	11,338	99.1%	6,421	99.0%	355	97.5%	5,810	98.8%
Small cell (8041-8045)	13,947	13.0%	12,119	13.7%	1,122	9.8%	608	9.4%	61	16.8%	706	12.0%
Non-small cell ^d	92,205	85.9%	75,533	85.2%	10,216	89.3%	5,813	89.6%	294	80.8%	5,104	86.8%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	25,050	23.3%	20,702	23.4%	2,893	25.3%	1,250	19.3%	106	29.1%	1,221	20.8%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	36,582	34.1%	29,899	33.7%	3,756	32.8%	2,728	42.1%	73	20.1%	2,106	35.8%
Large cell (8011-8015)	3,782	3.5%	3,064	3.5%	473	4.1%	222	3.4%	-	-	228	3.9%
Other non-small cell ^e	26,791	25.0%	21,868	24.7%	3,094	27.0%	1,613	24.9%	105	28.8%	1,549	26.3%
Sarcoma (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	200	0.2%	168	0.2%	16	0.1%	-	-	-	-	-	-
Other specified types ^f (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	74	0.1%	69	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	881	0.8%	730	0.8%	89	0.8%	52	0.8%	-	-	51	0.9%
Total	107,307	100.0%	88,619	100.0%	11,445	100.0%	6,486	100.0%	364	100.0%	5,879	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^g Other specific types includes melanomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	92,584	98.9%	78,748	98.9%	8,700	98.9%	4,460	99.1%	335	98.5%	4,716	98.5%
Small cell (8041-8045)	13,879	14.8%	12,435	15.6%	1,045	11.9%	281	6.2%	74	21.8%	569	11.9%
Non-small cell ^d	78,705	84.1%	66,313	83.3%	7,655	87.0%	4,179	92.9%	261	76.8%	4,147	86.6%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	14,632	15.6%	12,511	15.7%	1,592	18.1%	418	9.3%	74	21.8%	616	12.9%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	38,785	41.4%	32,406	40.7%	3,493	39.7%	2,646	58.8%	88	25.9%	2,170	45.3%
Large cell (8011-8015)	2,762	3.0%	2,292	2.9%	334	3.8%	113	2.5%	-	-	135	2.8%
Other non-small cell ^e	22,526	24.1%	19,104	24.0%	2,236	25.4%	1,002	22.3%	87	25.6%	1,226	25.6%
Sarcoma (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	155	0.2%	134	0.2%	-	-	-	-	-	-	-	-
Other specified types ^f (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	70	0.1%	60	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	793	0.8%	684	0.9%	74	0.8%	31	0.7%	-	-	50	1.0%
Total	93,602	100.0%	79,626	100.0%	8,794	100.0%	4,499	100.0%	340	100.0%	4,787	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^g Other specific types includes melanomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	32,099	83.0%	2,602	94.9%	10,484	96.7%	972	21.1%	2,160	96.0%
Squamous cell carcinoma (8070-8078,8083-8084)	31,094	80.4%	2,509	91.5%	10,289	94.9%	915	19.9%	2,133	94.8%
Adenocarcinoma (8050,8140-8147,8160-8162,8180-8221, 8250-8507,8514,8520-8551,8560,8570-8574, 8576,8940-8941)	4,290	11.1%	99	3.6%	172	1.6%	2,932	63.7%	69	3.1%
Other specific carcinomas (8012-8015,8030-8046,8150-8155, 8170-8180,8230-8249,8508, 8510-8513,8561-8562,8575,8580-8671)	444	1.1%	-	-	27	0.2%	234	5.1%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,376	3.6%	-	-	112	1.0%	311	6.8%	-	-
Sarcoma and soft tissue (8680-8713,8800-8921,8990-8991,9040-9044, 9120-9136,9150-9252,9370-9373,9540-9582)	179	0.5%	-	-	20	0.2%	47	1.0%	-	-
Other specific types (8720-8790,8930-8936,8950-8983,9060-9110, 9260-9365,9380-9539)	189	0.5%	-	-	-	-	74	1.6%	-	-
Unspecified (8000-8005)	106	0.3%	-	-	18	0.2%	34	0.7%	-	-
Total	38,683	100.0%	2,743	100.0%	10,842	100.0%	4,604	100.0%	2,250	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b	4,297	80.0%	1,567	63.6%	7,099	97.0%	2,367	96.5%	551	86.6%
Squamous cell carcinoma	4,066	75.7%	1,298	52.7%	6,998	95.6%	2,339	95.4%	547	86.0%
Adenocarcinoma	872	16.2%	59	2.4%	51	0.7%	18	0.7%	18	2.8%
Other specific carcinomas	21	0.4%	73	3.0%	36	0.5%	25	1.0%	-	-
Unspecified, Carcinoma, NOS	57	1.1%	706	28.6%	111	1.5%	26	1.1%	32	5.0%
Sarcoma and soft tissue	34	0.6%	42	1.7%	-	-	-	-	-	-
Other specific types	72	1.3%	-	-	-	-	-	-	-	-
Unspecified	16	0.3%	-	-	-	-	-	-	-	-
Total	5,369	100.0%	2,465	100.0%	7,322	100.0%	2,452	100.0%	636	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	22,477	92.4%	19,119	92.7%	1,539	89.5%	1,580	91.0%	108	91.5%	2,303	87.3%
Epidermoid carcinoma ^d (8051-8131)	175	0.7%	136	0.7%	-	-	21	1.2%	-	-	25	0.9%
Adenocarcinoma ^e	20,658	84.9%	17,624	85.5%	1,355	78.8%	1,467	84.5%	98	83.1%	2,064	78.3%
Adenocarcinoma, NOS (8140)	3,263	13.4%	2,720	13.2%	319	18.6%	199	11.5%	-	-	325	12.3%
Papillary adenocarcinoma, NOS (8050,8260)	584	2.4%	496	2.4%	55	3.2%	26	1.5%	-	-	48	1.8%
Clear cell adenocarcinoma (8310,9110)	1,239	5.1%	987	4.8%	41	2.4%	201	11.6%	-	-	104	3.9%
Endometrioid carcinoma (8380-8383,8570)	2,528	10.4%	2,152	10.4%	115	6.7%	230	13.2%	-	-	229	8.7%
Cystadenocarcinoma, NOS (8440,8450)	153	0.6%	117	0.6%	24	1.4%	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	3,033	12.5%	2,607	12.6%	184	10.7%	204	11.8%	18	15.3%	308	11.7%
Papillary serous cystadenocarcinoma (8460-8462)	7,224	29.7%	6,366	30.9%	447	26.0%	350	20.2%	35	29.7%	697	26.4%
Mucinous cystadenocarcinoma (8470-8473)	547	2.2%	451	2.2%	28	1.6%	54	3.1%	-	-	87	3.3%
Mucinous adenocarcinoma (8480,8482)	865	3.6%	692	3.4%	77	4.5%	84	4.8%	-	-	108	4.1%
Mucin-producing adenocarcinoma(8481)	82	0.3%	66	0.3%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,140	4.7%	970	4.7%	55	3.2%	104	6.0%	-	-	129	4.9%
Other specific carcinomas ^g	541	2.2%	427	2.1%	77	4.5%	31	1.8%	-	-	80	3.0%
Stromal cell tumor (8620-8631,8650)	318	1.3%	236	1.1%	59	3.4%	19	1.1%	-	-	45	1.7%
Other ^h	223	0.9%	191	0.9%	18	1.0%	-	-	-	-	35	1.3%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,103	4.5%	932	4.5%	93	5.4%	61	3.5%	-	-	134	5.1%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	84	0.3%	63	0.3%	17	1.0%	-	-	-	-	-	-
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,595	6.6%	1,283	6.2%	149	8.7%	143	8.2%	-	-	287	10.9%
Mullerian mixed tumor (8950-8951,8980)	671	2.8%	573	2.8%	48	2.8%	44	2.5%	-	-	58	2.2%
Teratoma, malignant (9080-9085,9102)	354	1.5%	264	1.3%	36	2.1%	48	2.8%	-	-	110	4.2%
Other	570	2.3%	446	2.2%	65	3.8%	51	2.9%	-	-	119	4.5%
Unspecified (8000-8005)	179	0.7%	151	0.7%	-	-	-	-	-	-	32	1.2%
Total ^d	24,335	100.0%	20,616	100.0%	1,719	100.0%	1,736	100.0%	118	100.0%	2,637	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	32,680	97.9%	26,728	97.9%	3,522	98.3%	2,148	98.1%	137	96.5%	3,110	97.7%
Epidermoid carcinoma ^d (8051-8131)	68	0.2%	49	0.2%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	28,540	85.5%	23,406	85.7%	3,055	85.2%	1,835	83.8%	123	86.6%	2,691	84.6%
Adenocarcinoma, NOS (8140)	23,034	69.0%	18,895	69.2%	2,507	69.9%	1,433	65.4%	103	72.5%	2,170	68.2%
Papillary adenocarcinoma, NOS (8260)	70	0.2%	59	0.2%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	940	2.8%	782	2.9%	82	2.3%	68	3.1%	-	-	82	2.6%
Mucin-producing adenocarcinoma (8481)	626	1.9%	506	1.9%	92	2.6%	25	1.1%	-	-	58	1.8%
Infiltrating duct carcinoma (8500-8503,8507,8514)	2,967	8.9%	2,416	8.8%	286	8.0%	241	11.0%	-	-	248	7.8%
Other adenocarcinoma ^f	903	2.7%	748	2.7%	84	2.3%	63	2.9%	-	-	120	3.8%
Other specific carcinomas ^g	1,924	5.8%	1,568	5.7%	200	5.6%	129	5.9%	-	-	191	6.0%
Islet cell carcinoma (8150-8155)	360	1.1%	298	1.1%	31	0.9%	27	1.2%	-	-	28	0.9%
Other carcinomas ^h	1,564	4.7%	1,270	4.7%	169	4.7%	102	4.7%	-	-	163	5.1%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,148	6.4%	1,705	6.2%	257	7.2%	176	8.0%	-	-	224	7.0%
Sarcoma and other soft tissue tumors ⁱ	31	0.1%	26	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	23	0.1%	19	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	640	1.9%	536	2.0%	54	1.5%	41	1.9%	-	-	66	2.1%
Total	33,374	100.0%	27,309	100.0%	3,584	100.0%	2,190	100.0%	142	100.0%	3,182	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	26,449	94.7%	19,123	95.0%	3,141	91.4%	3,823	95.8%	202	97.1%	4,487	96.8%
Epidermoid carcinoma ^d (8051-8131)	212	0.8%	156	0.8%	45	1.3%	-	-	-	-	17	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	204	0.7%	151	0.8%	43	1.3%	-	-	-	-	-	-
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	24,122	86.3%	17,326	86.1%	2,827	82.3%	3,665	91.8%	179	86.1%	4,091	88.3%
Adenocarcinoma, NOS (8140)	13,916	49.8%	10,332	51.3%	1,634	47.5%	1,777	44.5%	106	51.0%	2,021	43.6%
Adenocarcinoma, intestinal type (8144)	2,226	8.0%	1,323	6.6%	288	8.4%	580	14.5%	21	10.1%	378	8.2%
Carcinoma, diffuse type (8145)	813	2.9%	516	2.6%	81	2.4%	205	5.1%	-	-	172	3.7%
Linitus plastica (8142)	305	1.1%	235	1.2%	25	0.7%	42	1.1%	-	-	81	1.7%
Mucinous adenocarcinoma (8470-8473,8480,8482)	451	1.6%	324	1.6%	67	1.9%	55	1.4%	-	-	55	1.2%
Mucin-producing adenocarcinoma (8481)	244	0.9%	185	0.9%	37	1.1%	17	0.4%	-	-	27	0.6%
Signet ring adenocarcinoma (8490)	5,066	18.1%	3,657	18.2%	558	16.2%	795	19.9%	30	14.4%	1,161	25.1%
Other adenocarcinomas ^e	1,101	3.9%	754	3.7%	137	4.0%	194	4.9%	-	-	196	4.2%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	1,399	5.0%	1,114	5.5%	173	5.0%	73	1.8%	-	-	246	5.3%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	716	2.6%	527	2.6%	96	2.8%	76	1.9%	-	-	133	2.9%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	81	0.3%	65	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,270	4.5%	839	4.2%	267	7.8%	147	3.7%	-	-	118	2.5%
Unspecified (8000-8005)	138	0.5%	98	0.5%	18	0.5%	18	0.5%	-	-	17	0.4%
Total ^d	27,939	100.0%	20,126	100.0%	3,437	100.0%	3,992	100.0%	208	100.0%	4,633	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	38,847	99.8%	32,187	99.8%	2,298	99.7%	3,690	99.8%	153	100.0%	5,269	99.8%
Epidermoid carcinoma ^d (8051-8131)	46	0.1%	38	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	37,556	96.5%	31,126	96.5%	2,202	95.5%	3,584	97.0%	148	96.7%	5,116	96.9%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	33,397	85.8%	27,742	86.0%	1,831	79.4%	3,255	88.1%	130	85.0%	4,688	88.8%
Follicular carcinoma (8330-8332,8335)	2,519	6.5%	1,990	6.2%	253	11.0%	225	6.1%	-	-	265	5.0%
Oxyphilic (8290)	1,238	3.2%	1,060	3.3%	92	4.0%	71	1.9%	-	-	116	2.2%
Other specific carcinomas ^f	647	1.7%	549	1.7%	47	2.0%	37	1.0%	-	-	80	1.5%
Medullary carcinoma (8510)	609	1.6%	518	1.6%	44	1.9%	34	0.9%	-	-	78	1.5%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	598	1.5%	474	1.5%	47	2.0%	66	1.8%	-	-	66	1.2%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	377	1.0%	302	0.9%	29	1.3%	41	1.1%	-	-	36	0.7%
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^g	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	74	0.2%	55	0.2%	-	-	-	-	-	-	-	-
Total	38,935	100.0%	32,253	100.0%	2,305	100.0%	3,696	100.0%	153	100.0%	5,281	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^g Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.